Literature DB >> 9308909

A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1.

M P Pritchard1, R Ossetian, D N Li, C J Henderson, B Burchell, C R Wolf, T Friedberg.   

Abstract

Heterologous expression of unmodified recombinant human cytochrome P450 enzymes (P450s) in Escherichia coli has proved to be extremely difficult. To date, high-level expression has only been achieved after altering the 5'-end of the native cDNA, resulting in amino acid changes within the P450 protein chain. We have devised a strategy whereby unmodified P450s can be expressed to high levels in E. coli, by making NH2-terminal translational fusions to bacterial leader sequences. Using this approach, we initially tested two leader sequences, pelB and ompA, fused to CYP3A4. These were compared with an expression construct producing a conventional NH2-terminally modified CYP3A4 (17alpha-3A4). Both leader constructs produced spectrally active, functional protein. Furthermore, the ompA-3A4 fusion gave higher levels of expression, and a marked improvement in the recovery of active P450 in bacterial membrane fractions, when compared with 17alpha-3A4. We then tested the ompA leader with CYP2A6 and CYP2E1, again comparing with the conventional (17alpha-) approach. As before, the leader construct produced active enzyme, and, for CYP2E1 at least, gave a higher level of expression than the 17alpha-construct. The ompA fusion strategy thus appears to represent a significant advance for the expression of P450s in E. coli, circumventing the previous need for individual optimization of P450 sequences for expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308909     DOI: 10.1006/abbi.1997.0265

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  18 in total

1.  Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5.

Authors:  Robert D Finn; Lesley A McLaughlin; Sebastien Ronseaux; Ian Rosewell; J Brian Houston; Colin J Henderson; C Roland Wolf
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

2.  Cytochrome P450-mediated 17beta-estradiol metabolism in zebrafish (Danio rerio).

Authors:  Marcus L Scornaienchi; Cammi Thornton; Kristine L Willett; Joanna Y Wilson
Journal:  J Endocrinol       Date:  2010-06-03       Impact factor: 4.286

3.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

Authors:  G Smith; S Modi; I Pillai; L Y Lian; M J Sutcliffe; M P Pritchard; T Friedberg; G C Roberts; C R Wolf
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

4.  Comparison of microbial hosts and expression systems for mammalian CYP1A1 catalysis.

Authors:  Sjef Cornelissen; Mattijs K Julsing; Andreas Schmid; Bruno Bühler
Journal:  J Ind Microbiol Biotechnol       Date:  2011-08-24       Impact factor: 3.346

5.  Export of cytochrome P450 105D1 to the periplasmic space of Escherichia coli.

Authors:  M A Kaderbhai; C C Ugochukwu; S L Kelly; D C Lamb
Journal:  Appl Environ Microbiol       Date:  2001-05       Impact factor: 4.792

6.  Engineering of a functional human NADH-dependent cytochrome P450 system.

Authors:  O Döhr; M J Paine; T Friedberg; G C Roberts; C R Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 7.  Expression and secretion of proteins in E. coli.

Authors:  O Pines; M Inouye
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

8.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

9.  A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.

Authors:  Colin J Henderson; Lesley A McLaughlin; Robert D Finn; Sebastien Ronseaux; Yury Kapelyukh; C Roland Wolf
Journal:  Drug Metab Dispos       Date:  2013-10-10       Impact factor: 3.922

10.  The influence of microbial physiology on biocatalyst activity and efficiency in the terminal hydroxylation of n-octane using Escherichia coli expressing the alkane hydroxylase, CYP153A6.

Authors:  Oluwafemi A Olaofe; Caryn J Fenner; Rama Krishna Gudiminchi; Martha S Smit; Susan T L Harrison
Journal:  Microb Cell Fact       Date:  2013-01-25       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.